[Effect of Y-12, 141 on immune response of dd mice. Studies on anti-allergic agents, V. (author's transl)]

Abstract

Mice were immunized with sheep red blood cells (SRBC) at day 0, and hemagglutinin (HA) titer of the serum, hemolytic plaque forming cells (HPFC) in the spleen cells and rosette forming cells (RFC) in both the spleen and thymus cells were assayed at day 5. The immune responses in the mice immunized with 1 X 10(8) SRBC intravenously were not affected by Y-12, 141 given orally for 5 days (0 approximately 4 days) at doses of 30 approximately 100 mg/kg, but were suppressed by cyclophosphamide (10 approximately 30 mg/kg p.o.) and D-penicillamine (100 mg/kg p.o.). The treatment of the mice with levamisole (1 approximately 30 mg/kg p.o.) resulted in the increase of RFC number in the spleen. Levamisole increased the number of RFC in the mice immunized with 5 X 10(6) approximately 10(8) SRBC. On the other hand, Y-12,141 (10 approximately 30 mg/kg p.o.) increased spleen RFC number in the mice immunized with 5 approximately 10 X 10(6) SRBC. Y-12,141 and levamisole given orally on day 0, 1 or 2 increased spleen RFC number in the mice immunized with 5 X 10(6) SRBC. D-Penicillamine given orally for 3 days (-2 approximately 0 days) also potentiated spleen rosette formation. The decreased number of RFC in the spleen and thymus by cyclophosphamide given orally in a dose of 20 mg/kg was restored by the treatment with Y-12,141 (3 approximately 30 mg/kg) and levamisole (1 approximately 30 mg/kg). In addition, these agents suppressed 19S HA titer, and elevated 7S HA titer in the cyclophosphamide-treated mice. Prednisolone given orally in a dose of 30 mg/kg also decreased the number of RFC in the spleen. This decrease was restored by the treatment with Y-12,141 and levamisole. These findings suggest that Y-12,141 has a capacity to potentiate the immune response in mice immunized with low doses of SRBC and to restore the decrease of immune response caused by immunosuppressive drugs such as cyclophosphamide and prendisolone.